The U.S. government is taking steps to distribute Pfizer’s oral anti-coronavirus drug Paxlovid to testing and treatment sites in response to a possible new wave of outbreaks due to this summer’s travel season.
The first COVID-19 testing and treatment site backed by the U.S. federal government will open in Rhode Island on May 26, and patients who test positive will be able to receive treatment at the site. Over the next few weeks, such outlets will gradually be piloted in Massachusetts and New York City.
The administration will send federal medical experts next week to testing sites operated in Minnesota, which it plans to upgrade to testing and treatment centers. In addition to this, the government has created medication instructions for local doctors to clarify how to manage Paxlovid interactions with other medications. It is understood that the government has ordered 20 million courses of Paxlovid. But if the drug’s use remains high, the stockpiles are expected to remain at risk of shortages this winter.
According to the US Centers for Disease Control and Prevention, as of May 25, the cumulative number of infections in the United States was about 83.4 million, with an average daily infection rate of about 104,000.
edit/irisz
This article is reprinted from: https://news.futunn.com/post/15910340?src=3&report_type=market&report_id=206713&futusource=news_headline_list
This site is for inclusion only, and the copyright belongs to the original author.